21 Clinical, Medical & Diagnostic Products Dispense pumps address fl uidic challenges in evolving medical-IVD instruments
As the landscape of medical in vitro diagnostics (IVD) rapidly evolves, instrument designers face multifaceted challenges in meeting emerging demands, especially in critical areas such as COVID-19 testing. This growing market necessitates greater efficiency, throughput, and reliability, all while simplifying fluidic techniques and instrument size to cater to point-of-care testing without sacrificing performance. Additionally, the trend towards smaller specimen samples for accurate reagent delivery amplifies the need for precision.
In tackling these challenges, optimised fluidic techniques emerge as crucial components such as variable volume dispense pumps. The LPD Series of Variable Volume Dispense Pumps, developed by ‘Innovation in Miniature’ specialists, The Lee Company, stands as a testament to success in this realm. These pumps, a mainstay in the medical/IVD sector, exemplify size efficiency and exceptional durability, capable of enduring up to 10 million cycles, a feat unmatched in the field. This longevity ensures seamless integration into systems without recurring service interruptions.
A distinguishing factor of the LPD Series pumps is their maintenance-free operation. Unlike traditional syringe pumps that require periodic upkeep, the LPD Series boasts both extensive cycle ratings and reliability. This flexibility empowers strategic pump placement based solely on fluidic needs, leading to accelerated aspiration rates, enhanced throughput, and shorter testing cycles. Integration of valves and components in the port head design minimises leakage points, offering design flexibility.
The LPD Series pump emerges as an indispensable tool in overcoming the challenges inherent in cutting-edge diagnostic instruments, setting benchmarks in performance and reliability. It finds success in applications ranging from reagent dispensing and aliquoting to probe washing and sample preparation, ensuring steadfast reliability and precise dispense accuracy at a cost-effective investment.
In an era of rapid medical IVD advancements, the LPD Series Variable Volume Dispense Pumps provides a solution that helps instrument designers achieve efficient, reliable, and accurate results. By optimising fluidic techniques and embodying longevity, these pumps contribute to the evolution of medical-IVD instruments and their critical role in modern healthcare.
More information online:
ilmt.co/PL/x4XX 61035pr@reply-direct.com
Revolutionising tumour screening with lab-on-chip technology
Glasgow-based company, ScreenIn3D, highlights their distinctive lab-on-a-chip technology, which empowers cancer researchers to miniaturise their examination of biopsy tissue samples across an extensive array of modalities. This innovation also facilitates the evaluation of both individual and combined drug treatments on viable tissue samples.
By harnessing the latest advances in microfluidics and 3D cell culture, ScreenIn3D’s unique chip technology empowers researchers to conduct scores of 3D cancer screening experiments using as few as 1000 cells. Backed by investments from Gabriel Investments Ltd, Scottish Enterprise, and the University of Strathclyde’s Entrepreneurial Fund, ScreenIn3D is poised to enhance the platform’s capabilities for testing novel tumour indications and to scale up chip production. This expansion aims to extend the platform’s availability to pharmaceutical and biotech firms seeking to license the technology for internal utilisation. The integration of this ground-breaking technology into testing protocols holds the potential to revolutionise pharmaceutical companies’ capacity to rapidly assess drug effectiveness on patient-derived tumours. This advancement amplifies their initiatives by generating more physiologically relevant data, setting it apart from conventional biopsy approaches reliant on non-viable or deceased cells.
Dr Michele Zagnoni, Chief Executive Officer of ScreenIn3D, commented: “There are challenges with evaluating solid tumours, not just cancerous cells but those surrounding them and their interactions with immuno-cells. Tumour tissue is a precious resource, which is underutilised in drug development due to high cost and its limited quantity. Our technology offers a completely new way to test a vast number of combination therapies on patient-derived samples, offering drug developers increased opportunities of finding new treatments, quicker and with less failures.”
ScreenIn3D co-founder, Alex Sim, further continued: “Drug development is expensive. We have developed a technology platform which could accelerate the development of therapies on models that are representative of what happens in the body during disease. This bold approach will unlock remarkable advancements for precision oncology. For example, how to tailor an anticancer treatment to an individual patient, reduce animal tests and profoundly impact the way drugs can be developed for other diseases in the future.”
More information online:
ilmt.co/PL/lZEj 61056pr@reply-direct.com
Custom monoclonal antibody reveals HER2+ breast cancer target
AMSBIO has supplied a tailor-made monoclonal antibody (mAB) to TU Dortmund researchers in Germany. This mAB aims to decode EDI3’s role in breast cancer development, how it’s controlled by HER2 signalling, and its therapeutic potential.
HER2+ breast cancer, marked by excessive Human Epidermal Growth Factor Receptor 2 (HER2) expression, is an extremely aggressive cancer subtype. Despite advancements in HER2-targeted therapies, the persistence of treatment resistance, both acquired and inherent, necessitates exploration of alternative therapeutic targets.
Under the leadership of Dr Rosemarie Marchan, a group of researchers has undertaken an extensive study to investigate the clinical significance of EDI3, a glycerophosphodiesterase enzyme linked to choline metabolism, within HER2-positive breast cancer. They utilised the custom monoclonal antibody against EID3, provided by AMSBIO, in their research.
Dr Marchan commented: “We have tested many off-the-shelf antibodies over the years, with little to no success. We have also contracted companies to
create a custom antibody for us, but again with limited success. Therefore, we are very thankful a few years ago that we were able to get a great antibody against EID3 from AMSBIO. Using this precious antibody our team has been able to demonstrate that inhibiting EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.”
Read the full case study describing the work of Dr Marchan and her team in the Leibniz Research Centre for Working Environment and Human Factors (IfADo) at the TU Dortmund:
ilmt.co/PL/JeQM
With a track record of providing products to numerous industrial and academic projects over the past two decades, AMSBIO has gained widespread recognition as a leading supplier of both ready-made and tailored antibodies. Their services encompass the creation of custom monoclonal antibodies tailored to your specific target antigen, delivering a well-informed and high- quality solution.
More information online:
ilmt.co/PL/dL1K 61146pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
